The present invention relates to medical devices and, more specifically without limitation, to implanted medical devices.
Epilepsy affects about 2.3 million Americans, and its direct and indirect annual costs amount to approximately $12.5 billion. Although anti-epileptic drugs are useful, 20-30% of persons are not helped by them and up to 30% of those treated have intolerable or serious side effects.
Recently published studies demonstrate the importance of quantitative analysis of brain signals for automated warning and blockage of seizures, optimization of existing therapies and development of new ones. Cardiac activity is under cerebral control. That is, certain changes in global, regional or focal brain activity, either physiological or pathological, modify heart activity. Epileptic seizures are one of the pathological brain states associated with changes in heart activity including but not limited to changes in heart rate, most frequently an increase and referred to as ictal tachycardia, or in other indices of cardiac function such as R-R variability. The incidence of heart changes increases as the seizure spreads outside its site of origin to other brain regions being, for example invariably present in all subjects with primarily or secondarily generalized tonic-clonic seizures (“convulsions”), in whom purportedly, most or all of the brain is involved. These changes reflect shifts in the ongoing interplay between sympathetic and parasympathetic influences, which can be quantified using time or frequency domain methods of analysis. For example, tachycardia precedes electrographic onset of temporal lobe seizures by several seconds, as ascertained via scalp electrodes (EEG), while combined activation of parasympathetic and sympathetic systems as estimated by using spectral analysis of oscillations in R-R intervals at respiratory and non-respiratory frequencies, may be detectable minutes in advance of seizure onset. Since these changes may precede visible electrographic or behavioral manifestations indicative of seizures and even of the so-called “aura,” they may have predictive value. Real-time prediction or detection of epileptic seizures, based on extracerebral sources such as the heart, is of great clinical and practical value as it obviates the reliance on cerebral signals which are highly complex and of high dimensionality and whose origin may not only be difficult to localize but quite often requires invasive intracranial implantation of electrodes or other sensors.
While methods presently exist to detect seizures using cardiac signals and quantify their characteristics, for example as described in U.S. Pat. No. 6,341,236 which is incorporated herein by reference in its entirety, no system for logging the times of seizures and their quantitative characteristics, such as date and time of occurrence, and duration based on the degree of cardiac changes, and for using this information in the objective assessment of seizure frequency and of therapeutic intervention, presently exists. This is partially due to the impact of artifacts (noise) on EKG signal analysis which can lead to inaccuracies in heart rate assessments.
Thus, the need exists for a system and method for logging seizures, or other events originating in the brain that impact cardiac activity, and associated event characteristics such as frequency, duration, intensity, and severity. Moreover, this system and method needs to be robust in the presence of artifacts or other sources of noise. The need also exists for a minimally invasive system and method to provide effective and objective means for assessing the efficacy of therapies used to control seizures.
Changes in heart activity associated with seizures can be used to automatically and in real-time detect the seizures, quantify their frequency, duration, intensity, or severity as reflected in the cardiac signal changes, predict their electrographic or clinical onset in a subset of cases, and control the seizures via therapeutic intervention. The present invention enables the logging of this information and its utilization to objectively assess the efficacy of an applied therapy. To accomplish this task with improved robustness in the presence of signal artifacts or noise, the invention can utilize EKG and complementary information obtained from other signals representative of cardiac function such as the phonocardiogram (PKG), echocardiogram, or ultrasound.
Changes in certain types of global, regional or focal brain activity, either physiological or pathological, modify heart activity. Epileptic seizures are one important example of a pathological brain state with demonstrated association to changes in heart activity. The incidence of heart changes increases as the seizure spreads outside its site of origin to other brain regions being, for example invariably present in all subjects with primarily or secondarily generalized tonic-clonic seizures (“convulsions”), in whom purportedly, most or all of the brain is involved. Real-time prediction or detection, and quantitative analysis of epileptic seizures, based on extracerebral sources such as the heart, is of great clinical and practical value as it obviates the reliance on cerebral signals which are highly complex and of high dimensionality, and whose origin may not only be difficult to localize but quite often requires invasive intracranial implantation of electrodes or other sensors. The invention disclosed herein, and depicted schematically in
While methods presently exist to detect seizures using cardiac signals and quantify their characteristics, for example as described in U.S. Pat. No. 6,341,236, no system presently exists for logging these quantitative characteristics, such as times of occurrence, durations and degrees of cardiac changes associated with seizures or other underlying brain events and for using this information in objective assessment of the neurological disorder and of efficacy of therapeutic intervention. This is partially due to the impact of artifacts (noise) on EKG signal analysis which can lead to inaccuracies in heart rate assessments.
Seizures often are associated with movement, muscle, and other artifacts that can obscure or distort the EKG making it difficult or impossible to extract the important information contained in the contaminated signals.
The PKG can be used instead of EKG for tracking heart rate and its variability given the high temporal correlation between the S1 and the QRS complex. Simultaneous use of PKG and EKG allows the system access to good quality information for more complete and accurate tracking of the cardiac system dynamics and, indirectly, of brain dynamics effecting the heart. Those skilled in the art can appreciate that many other types of physical or chemical heart signals suitable for use with implantable devices can also be used in addition to, or instead of, EKG and PKG for this purpose.
In view of the clinical importance of real-time automated quantitative seizure analysis and the greater signal-to-noise ratio and shorter propagation time from source to sensor, and ease of use of heart signals (electrocardiogram, EKG, or phonocardiogram, PKG) compared to scalp signals (EEG) or intracranial recording of electrical signals (ECoG), the approach of the present invention disclosed herein makes use of these signals for a) the invasive or non-invasive extracerebral, real-time automated detection of seizures based on heart signals; b) the logging of frequency, date/time of occurrence, relative intensity and relative duration of seizures; c) the anticipation of electrographic or behavioral seizure onset and/or loss of function in a subgroup of subjects with epilepsy, for automated warning and other useful purposes; and d) the automated delivery of a selected therapy, either contingent or closed-loop. Additionally and of equal importance is the ability to detect, in real-time, cardiac rhythm abnormalities, which may be life-threatening and which are temporally correlated with seizures or occur in between seizures and to provide appropriate intervention such as pacing or defibrillation.
Use of cardiac signals such as EKG and/or PKG for the automated detection of seizures, and in certain cases for the anticipation of their onset, will complement and, in a subgroup of subjects with pharmaco-resistant epilepsy, may replace scalp or intracranial (invasive) acquisition of cortical signals for automated warning and/or therapy delivery and in either case will allow for seizure logging and other tasks. One of the main advantages of using EKG/PKG for seizure detection is that unlike methods based on cortical signals recorded either directly from the cortex, which requires a craniotomy or burr hole, or indirectly from the scalp (EEG), it is not critically, dependent on accurate placement of electrodes and, in a subset of cases, the onset of heart changes may even precede scalp or behavioral changes providing yet another advantage.
Heart signals, can be obtained from several body sites obviating, in a subgroup of patients, the need for surgery, thus decreasing the inconvenience, stress, cost, potential morbidity and recovery time associated with such procedures. Furthermore, the wealth of commercially available, low power, implantable devices for analysis and control of heart signals can be easily leveraged for this application. Another advantage of EKG over EEG or ECoG is its lower dimensionality and relative simplicity wherein a single channel recording is sufficient for capturing all of the information necessary for the tasks at hand.
Those skilled in the art can appreciate that in certain cases or situations, dual, simultaneous monitoring of brain and heart may be necessary or useful to improve detection of changes in either organ or to improve the efficacy of control measures. Also, undesirable changes in heart activity caused by abnormal brain activity may be better controlled by directing the intervention to the brain rather than to the heart. For instance, while asystole caused by seizures can be controlled using a demand pacemaker, a more definitive and rational approach is to prevent or block asystole-inducing seizures. It is clear that the dynamic interactions between heart and brain can be exploited to detect changes and to control them by monitoring either organ or both and by applying control to either of them, or to both.
Frei and Osorio and others, see for example U.S. Pat. No. 6,341,236, have disclosed methods for automated EKG analysis and detection of cardiac signal changes associated with epileptic seizures. The methods developed by Frei and Osorio are especially well-suited for seizure detection using heart signals, a task which requires analysis of data over very short windows (1-2 sec). The length requirements of other methods for standard low/ultra-low frequency band power assessments of heart rate variability, typically five-minute segments assumed to be stationary, are much longer than the duration of a seizure or a dangerous cardiac abnormality that may lead to sudden death. In addition, the assumptions regarding stationarity of the system/signal are counter to the well-known nonstationarity of the normal cardiac system. Given these deficiencies, it is therefore impractical to apply methods of heart signal analysis that require long segments of data, minutes for example, for the detection of phenomena for which warning and control must take place in a very short time period (e.g., under ten seconds) for purposes of safety and efficacy. Another advantage of the methods of the present invention is that they can be used to quantify the intensity, type, and evolution of cardiac changes, which in turn may be used to detect and estimate the duration and intensity of underlying brain state changes whether physiological or pathological. The changes in heart activity that may indicate a possible onset of a seizure (a pathologic state change) include, but are not limited to, changes in heart rate and heart rate variability and their interrelationship, rhythm, morphology of the P-QRS-T complex or of the length of the different intervals (e.g., Q-T).
One skilled in the art can appreciate that, in addition to the aforementioned methods, a number of methods for detection and analysis of cardiac signal changes exist in prior art, many of which have been implemented in hardware, software, or in a hybrid configuration, and which can be used, for example, to obtain the time of each heart beat as well as the interbeat (e.g., R-R) interval. One skilled in the art will appreciate for example, that the R-R interval times or other quantities representative of cardiac state may be processed/analyzed using methods in the time or frequency domains to generate a multitude of derivative signals/sequences or ratios from which a wealth of information can be obtained about the heart, including instantaneous heart rate (IHR), its average rate in fixed or moving windows of any desired length, and measures of heart rate variability (“HRV”) (e.g., standard deviation of means of R-R intervals in a moving window, or the second derivative of instantaneous heart rate, etc.) on any desired timescale but with emphasis on those timescales suitable for seizure detection. Changes in the distributions of these, or any other quantity derived from the time-of-beat sequence, as time evolves can be detected and quantified in real-time, for example using the “lambda estimator” as disclosed in Nikitin et al, U.S. Patent Application Publication No. 20030187621, or other statistical methods. Stereotypical patterns, if found in these data, may be learned over time as more seizures are recorded and analyzed. For example, cardiac data from a subject can be used to establish normal or baseline patterns for this subject and compared against moving windows of new data to determine deviations from normalcy or baseline, proximity to dangerous or undesirable patterns, and to quantify these deviations. Degree of absolute or relative changes in heart rate, heart rate variability, and their interrelationship, ST-wave depression, and QT prolongation are examples of such quantities. The time of specific changes and their duration and/or intensity are obtainable from these analyses. As in the aforementioned Nikitin et al reference, one skilled in the art will appreciate that the analysis of interest can be multifactorial and/or multidimensional. For example, U.S. Pat. No. 6,341,236 of Osorio and Frei disclosed that changes in the relationship between IHR and HRV provide information about heart function which is not obtainable if IHR and HRV are analyzed separately.
The aforementioned lambda estimator provides one of many possible examples illustrating how statistical changes in feature signals, even when multi-dimensional, obtained from cardiac recordings, such as EKG, can be quantified as they evolve. By applying thresholding techniques or, more generally, by identifying values of quantified features that are associated with particular cardiac or body states, e.g., seizures, the start and end of these state changes can be localized in time and their relative intensity quantified.
These analyses may also be applied to PKG signals in order to detect similar, complementary, or different changes reflective of heart state. Other measures that may be used by the present invention include but are not limited to: duration including time of onset and termination of changes in heart rate or in any of its derivatives; changes in heart rate variability or in any of its derivatives; changes in rhythmicity or in generation and conduction of electrical impulses; or changes in the acoustic properties of heart beats and their variability. It will be appreciated that additional information may be obtained through analysis of occurrence times of other EKG waveforms such as Q-T intervals, changes in spectral properties of the EKG or signal morphology, as well as time-of-beat information obtained from PKG such as s1-s1 intervals, amplitude (magnitude) of the signal, or changes in its waveshape and/or spectral characteristics, etc. For example, changes in the magnitude or rate of change of the high- and low-frequency components of the heart beat, using autoregressive, Fast Fourier, wavelets, Intrinsic Timescale Decomposition (U.S. patent application Ser. No. 10/684,189, filed Oct. 10, 2003), or other suitable techniques, may be used alone or combined with other cardiac measures to increase the sensitivity, specificity, and/or speed of prediction or detection of seizures or in their ability to quantify brain state changes. Other measures derived from the raw or processed signals that may be of additional use in the present invention include, but are not limited to, analysis of entropy, correlation dimension, Lyapunov exponents, measures of synchronization, fractal analysis, etc.
The real-time prediction, detection and quantification of seizures that is possible by using the methods disclosed herein and/or associated systems may be adapted or tailored to fit an individual's cardiac state change patterns or characteristics, thereby increasing sensitivity, specificity or speed of detection of state changes. The performance of the detection methods, such as sensitivity, specificity and speed, may be enhanced, if necessary, by characterizing baseline patterns for a subject and comparing them against moving windows of current data to determine and quantify deviations from baseline and proximity to patterns indicative of state change. These can be used, together with the frequency, intensity, and duration of heart signal changes, time to maximal deviation from baseline, time to recovery to baseline rates, for assessing a patient's condition, safety risks, and even efficacy of therapy. Moreover, degree of conformance to stereotypical cardiac signal patterns that may be associated with certain seizure types can be used to infer other severity-related measures such as degree of seizure spread in the brain. Simultaneous recording and analysis of other non-cardiac signals, such as muscle, joints, skin or peripheral nerves, may also improve prediction, detection and quantification of state changes. For example, the recording, analysis, and comparison of changes in cardiac signals during the state change of interest, e.g., seizures, to that obtained during activities such as exercise, can increase their sensitivity, specificity, and/or detection speed for real-time seizure detection purposes, or for detecting changes of body state. These processes may be carried out on- or off-line.
The information about heart state provided by the present invention can be used to compute seizure index, which is defined as the fraction of time spent in a seizure over a moving window of a given size. The information can also be used to determine seizure severity, e.g., using the product of intensity and duration. These and other measures may be logged as part of the present invention (or later computed from other logged information) and can provide valuable diagnostic and prognostic information, as well as information regarding efficacy of any therapy attempted during the period of monitoring/analysis. The set of logged information stored by the present invention can also be used to develop models that may allow or refine seizure prediction or detection (using cardiac signals or in general) and shed light on an individual's seizure dynamics.
The implantable or portable device implementing the present invention is configured to include a real-time clock and a rewritable, non-volatile memory, as well as one or more sensors for use in recording EKG, PKG and/or other representative signals indicative of cardiac function and/or state, such as echocardiogram, ultrasound, blood pressure, blood flow rate or volume, heart muscle tension, etc., and processing components capable of receiving, conditioning, and analyzing the EKG and/or PKG signals to detect and/or quantify events of interest such as seizures. The logging process consists of reading the real-time clock each time an event or cluster of events of a certain designated type occurs, and logging the clock time and variables associated with the quantification of the event to the non-volatile memory. These variables may include but are not limited to information obtained through processing of the signals, and/or the raw signals themselves, i.e., “loop recordings” of events.
The system of the present invention may be further configured with an output mechanism to: a) warn the subject of an impending seizure or other type of detected event such as a cardiac arrhythmia, low system battery, full memory, etc., and b) deliver a selected therapy to the subject when heart activity reaches or exceeds safe or prespecified limits. For example, Osorio and Frei in U.S. Pat. No. 6,341,236 disclose a means to trigger the pacing of the heart in the event of a seizure detected by analysis of EKG. Osorio et al., in U.S. Pat. No. 5,995,868, disclose a method of treating seizures by, among other methods, stimulating the brain, heart and/or vagus nerve when a seizure is detected. The output mechanism may include or be connected to a neurostimulator and/or a pacemaker to control brain and/or heart activity within prespecified tolerable/safe limits. Commonly used types of warnings include audio alarms with varied tones and/or combinations of short and long sounds, other types of acoustic devices, LED or other visual displays, e.g., flashing lights, etc., low-voltage so-called “tickler” stimulus, and communication with external devices, e.g., triggering an external device such as “calling 911,” etc.
Any additional implanted or portable device may also use the non-volatile memory for storing information about events through the use of a uni- or bi-directional communications protocol. For example, a pacemaker that detects an unusual EKG rhythm or heart beat pattern could trigger the device described herein that an event has occurred and potentially could communicate other features/attributes of the event, such as type, severity, etc., to the device for logging purposes. The system may also contain a display, or means to be externally interrogated, to review and/or download the information it has stored and/or logged for review by the user, subject, or physician. In addition to logging seizures or other events of neurological origin which impact the cardiac system, the system and method of the present invention can be used to objectively assess the efficacy of therapies used to control the occurrence or severity of these events. For example, when a subject takes medication in order to control his seizures, the availability of a seizure log that includes their time of occurrence, severity, and other features can be analyzed in reference to administration times and concentrations of medication or other therapy, which also can be logged by the system via the communication interface described above. Such comparisons enable the modeling and objective efficacy assessment of the effect of the therapy on the system. For instance, the seizure frequency measure plotted against the level of medication expected to be present in the subject's system as time evolves allows the user to optimize dosing levels and times to minimize seizure frequency.
Therapies administered to the subject based on the cardiac signal change may also include administration of a drug or medicament, features of which may include medicament type, dose, administration site, time of delivery, duration of delivery, rate of delivery, frequency of delivery, and inter-delivery interval. Therapies administered to the subject based on the cardiac signal change may include thermal regulation of the brain, features of which may include time of delivery, duration of delivery, rate of delivery, frequency of delivery, inter-delivery interval, administration site, intensity of therapy, and size of region affected by thermal regulation.
It is to be understood that while certain forms of the present invention have been illustrated and described herein, it is not to be limited to the specific forms or arrangement of parts described and shown.
This patent application is a divisional of U.S. patent application Ser. No. 10/997,540, filed Nov. 24, 2004 now U.S. Pat. No. 9,050,469, which claims priority of Provisional Patent Application No. 60/525,501 entitled “A Method and Apparatus for Logging, Warning and Treatment of Seizures Using Cardiac Signals,” filed Nov. 26, 2003, which are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3850161 | Liss | Nov 1974 | A |
4088138 | Diack et al. | May 1978 | A |
4172459 | Hepp | Oct 1979 | A |
4291699 | Geddes et al. | Sep 1981 | A |
4541432 | Molina-Negro et al. | Sep 1985 | A |
4573481 | Bullara | Mar 1986 | A |
4702254 | Zabara | Oct 1987 | A |
4867164 | Zabara | Sep 1989 | A |
4920979 | Bullara | May 1990 | A |
4949721 | Toriu et al. | Aug 1990 | A |
4979511 | Terry, Jr. | Dec 1990 | A |
5025807 | Zabara | Jun 1991 | A |
5113869 | Nappholz et al. | May 1992 | A |
5137020 | Wayne et al. | Aug 1992 | A |
5154172 | Terry, Jr. et al. | Oct 1992 | A |
5156148 | Cohen | Oct 1992 | A |
5179950 | Stanislaw | Jan 1993 | A |
5186170 | Varrichio et al. | Feb 1993 | A |
5188104 | Wernicke et al. | Feb 1993 | A |
5188106 | Nappholz et al. | Feb 1993 | A |
5203326 | Collins | Apr 1993 | A |
5205285 | Baker, Jr. | Apr 1993 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5215089 | Baker, Jr. | Jun 1993 | A |
5222494 | Baker, Jr. | Jun 1993 | A |
5231988 | Wernicke et al. | Aug 1993 | A |
5235980 | Varrichio et al. | Aug 1993 | A |
5237991 | Baker, Jr. et al. | Aug 1993 | A |
5243980 | Mehra | Sep 1993 | A |
5251634 | Weinberg | Oct 1993 | A |
5263480 | Wernicke et al. | Nov 1993 | A |
5269301 | Cohen | Dec 1993 | A |
5269302 | Swartz et al. | Dec 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5282474 | Sosa et al. | Feb 1994 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5304206 | Baker, Jr. et al. | Apr 1994 | A |
5311876 | Olsen et al. | May 1994 | A |
5313953 | Yomtov et al. | May 1994 | A |
5330505 | Cohen | Jul 1994 | A |
5330507 | Schwartz | Jul 1994 | A |
5330515 | Rutecki et al. | Jul 1994 | A |
5334221 | Bardy | Aug 1994 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5404877 | Nolan et al. | Apr 1995 | A |
5425373 | Causey, III | Jun 1995 | A |
5522862 | Testerman et al. | Jun 1996 | A |
5527344 | Arzbaecher et al. | Jun 1996 | A |
5540730 | Terry, Jr. et al. | Jul 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5571150 | Wernicke et al. | Nov 1996 | A |
5611350 | John | Mar 1997 | A |
5645570 | Corbucci | Jul 1997 | A |
5651378 | Matheny et al. | Jul 1997 | A |
5658318 | Stroetmann et al. | Aug 1997 | A |
5683422 | Rise et al. | Nov 1997 | A |
5690681 | Geddes et al. | Nov 1997 | A |
5690688 | Noren et al. | Nov 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5716377 | Rise et al. | Feb 1998 | A |
5720771 | Snell | Feb 1998 | A |
5743860 | Hively et al. | Apr 1998 | A |
5792186 | Rise | Aug 1998 | A |
5800474 | Benabid et al. | Sep 1998 | A |
5833709 | Rise et al. | Nov 1998 | A |
5913876 | Taylor et al. | Jun 1999 | A |
5916239 | Geddes et al. | Jun 1999 | A |
5928272 | Adkins | Jul 1999 | A |
5941906 | Barreras, Sr. et al. | Aug 1999 | A |
5942979 | Luppino | Aug 1999 | A |
5978702 | Ward et al. | Nov 1999 | A |
5987352 | Klein et al. | Nov 1999 | A |
5995868 | Dorfmeister et al. | Nov 1999 | A |
6016449 | Fischell et al. | Jan 2000 | A |
6018682 | Rise | Jan 2000 | A |
6061593 | Fischell et al. | May 2000 | A |
6073048 | Kieval et al. | Jun 2000 | A |
6083249 | Familoni | Jul 2000 | A |
6091992 | Bourgeois et al. | Jul 2000 | A |
6104956 | Naritoku et al. | Aug 2000 | A |
6115628 | Stadler et al. | Sep 2000 | A |
6115630 | Stadler et al. | Sep 2000 | A |
6128538 | Fischell et al. | Oct 2000 | A |
6134474 | Fischell et al. | Oct 2000 | A |
6167311 | Rezai | Dec 2000 | A |
6171239 | Humphrey | Jan 2001 | B1 |
6175764 | Loeb et al. | Jan 2001 | B1 |
6205359 | Boveja | Mar 2001 | B1 |
6208894 | Schulman et al. | Mar 2001 | B1 |
6208902 | Boveja | Mar 2001 | B1 |
6221908 | Kilgard et al. | Apr 2001 | B1 |
6248080 | Miesel et al. | Jun 2001 | B1 |
6253109 | Gielen | Jun 2001 | B1 |
6269270 | Boveja | Jul 2001 | B1 |
6272379 | Fischell et al. | Aug 2001 | B1 |
6304775 | Iasemidis et al. | Oct 2001 | B1 |
6324421 | Stadler et al. | Nov 2001 | B1 |
6337997 | Rise | Jan 2002 | B1 |
6339725 | Naritoku et al. | Jan 2002 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6356784 | Lozano et al. | Mar 2002 | B1 |
6356788 | Boveja | Mar 2002 | B2 |
6366813 | DiLorenzo | Apr 2002 | B1 |
6366814 | Boveja et al. | Apr 2002 | B1 |
6374140 | Rise | Apr 2002 | B1 |
6397100 | Stadler et al. | May 2002 | B2 |
6427086 | Fischell et al. | Jul 2002 | B1 |
6429217 | Puskas | Aug 2002 | B1 |
6449512 | Boveja | Sep 2002 | B1 |
6459936 | Fischell et al. | Oct 2002 | B2 |
6463328 | John | Oct 2002 | B1 |
6466822 | Pless | Oct 2002 | B1 |
6473639 | Fischell et al. | Oct 2002 | B1 |
6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
6477418 | Plicchi et al. | Nov 2002 | B2 |
6480743 | Kirkpatrick et al. | Nov 2002 | B1 |
6484132 | Hively et al. | Nov 2002 | B1 |
6501983 | Natarajan et al. | Dec 2002 | B1 |
6505074 | Boveja et al. | Jan 2003 | B2 |
6532388 | Hill et al. | Mar 2003 | B1 |
6542774 | Hill et al. | Apr 2003 | B2 |
6549804 | Osorio et al. | Apr 2003 | B1 |
6556868 | Naritoku et al. | Apr 2003 | B2 |
6560486 | Osorio et al. | May 2003 | B1 |
6564102 | Boveja | May 2003 | B1 |
6587719 | Barrett et al. | Jul 2003 | B1 |
6587727 | Osorio et al. | Jul 2003 | B2 |
6594524 | Esteller et al. | Jul 2003 | B2 |
6599250 | Webb et al. | Jul 2003 | B2 |
6609025 | Barrett et al. | Aug 2003 | B2 |
6610713 | Tracey | Aug 2003 | B2 |
6611715 | Boveja | Aug 2003 | B1 |
6615081 | Boveja | Sep 2003 | B1 |
6615085 | Boveja | Sep 2003 | B1 |
6622038 | Barrett et al. | Sep 2003 | B2 |
6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
6622047 | Barrett et al. | Sep 2003 | B2 |
6628985 | Sweeney et al. | Sep 2003 | B2 |
6628987 | Hill et al. | Sep 2003 | B1 |
6647296 | Fischell et al. | Nov 2003 | B2 |
6656125 | Misczynski et al. | Dec 2003 | B2 |
6656960 | Puskas | Dec 2003 | B2 |
6668191 | Boveja | Dec 2003 | B1 |
6671555 | Gielen et al. | Dec 2003 | B2 |
6671556 | Osorio et al. | Dec 2003 | B2 |
6684105 | Cohen et al. | Jan 2004 | B2 |
6721603 | Zabara et al. | Apr 2004 | B2 |
6735474 | Loeb et al. | May 2004 | B1 |
6738671 | Christophersom et al. | May 2004 | B2 |
6760626 | Boveja | Jul 2004 | B1 |
6768969 | Nikitin et al. | Jul 2004 | B1 |
6788975 | Whitehurst et al. | Sep 2004 | B1 |
6793670 | Osorio et al. | Sep 2004 | B2 |
6819953 | Yonce et al. | Nov 2004 | B2 |
6819956 | DiLorenzo | Nov 2004 | B2 |
6832114 | Whitehurst et al. | Dec 2004 | B1 |
6836685 | Fitz | Dec 2004 | B1 |
6885888 | Rezai | Apr 2005 | B2 |
6904390 | Nikitin et al. | Jun 2005 | B2 |
6920357 | Osorio et al. | Jul 2005 | B2 |
6934580 | Osorio et al. | Aug 2005 | B1 |
6934585 | Schloss | Aug 2005 | B1 |
6944501 | Pless | Sep 2005 | B1 |
6957107 | Rogers | Oct 2005 | B2 |
6961618 | Osorio et al. | Nov 2005 | B2 |
6985771 | Fischell et al. | Jan 2006 | B2 |
6990377 | Gliner et al. | Jan 2006 | B2 |
7006859 | Osorio et al. | Feb 2006 | B1 |
7006872 | Gielen et al. | Feb 2006 | B2 |
7010351 | Firlik et al. | Mar 2006 | B2 |
7024247 | Gliner et al. | Apr 2006 | B2 |
7054792 | Frei et al. | May 2006 | B2 |
7058453 | Nelson et al. | Jun 2006 | B2 |
7076288 | Skinner | Jul 2006 | B2 |
7079977 | Osorio et al. | Jul 2006 | B2 |
7134996 | Bardy | Nov 2006 | B2 |
7139677 | Hively et al. | Nov 2006 | B2 |
7146211 | Frei et al. | Dec 2006 | B2 |
7146217 | Firlik et al. | Dec 2006 | B2 |
7146218 | Esteller et al. | Dec 2006 | B2 |
7149572 | Frei et al. | Dec 2006 | B2 |
7164941 | Misczynski et al. | Jan 2007 | B2 |
7167750 | Knudson et al. | Jan 2007 | B2 |
7174206 | Frei et al. | Feb 2007 | B2 |
7177678 | Osorio et al. | Feb 2007 | B1 |
7188053 | Nikitin et al. | Mar 2007 | B2 |
7204833 | Osorio et al. | Apr 2007 | B1 |
7209786 | Brockway et al. | Apr 2007 | B2 |
7209787 | DiLorenzo | Apr 2007 | B2 |
7221981 | Gliner | May 2007 | B2 |
7228167 | Kara et al. | Jun 2007 | B2 |
7231254 | DiLorenzo | Jun 2007 | B2 |
7236830 | Gliner | Jun 2007 | B2 |
7236831 | Firlik et al. | Jun 2007 | B2 |
7242983 | Frei et al. | Jul 2007 | B2 |
7242984 | DiLorenzo | Jul 2007 | B2 |
7254439 | Misczynski et al. | Aug 2007 | B2 |
7263467 | Sackellares et al. | Aug 2007 | B2 |
7277758 | DiLorenzo | Oct 2007 | B2 |
7280867 | Frei et al. | Oct 2007 | B2 |
7282030 | Frei et al. | Oct 2007 | B2 |
7289844 | Misczynski et al. | Oct 2007 | B2 |
7292890 | Whitehurst et al. | Nov 2007 | B2 |
7295881 | Cohen et al. | Nov 2007 | B2 |
7299096 | Balzer et al. | Nov 2007 | B2 |
7302298 | Lowry et al. | Nov 2007 | B2 |
7305268 | Gliner et al. | Dec 2007 | B2 |
7321837 | Osorio et al. | Jan 2008 | B2 |
7324850 | Persen et al. | Jan 2008 | B2 |
7324851 | DiLorenzo | Jan 2008 | B1 |
7346391 | Osorio et al. | Mar 2008 | B1 |
7353063 | Simms, Jr. | Apr 2008 | B2 |
7353064 | Gliner et al. | Apr 2008 | B2 |
7373199 | Sackellares et al. | May 2008 | B2 |
7389144 | Osorio et al. | Jun 2008 | B1 |
7401008 | Frei et al. | Jul 2008 | B2 |
7403820 | DiLorenzo | Jul 2008 | B2 |
7433732 | Carney et al. | Oct 2008 | B1 |
20020072782 | Osorio et al. | Jun 2002 | A1 |
20020099417 | Naritoku et al. | Jul 2002 | A1 |
20020103512 | Echauz et al. | Aug 2002 | A1 |
20020116030 | Rezai | Aug 2002 | A1 |
20020151939 | Rezai | Oct 2002 | A1 |
20020188214 | Misczynski et al. | Dec 2002 | A1 |
20030074032 | Gliner | Apr 2003 | A1 |
20030083716 | Nicolelis et al. | May 2003 | A1 |
20030083726 | Zeijlemaker et al. | May 2003 | A1 |
20030125786 | Gliner et al. | Jul 2003 | A1 |
20030130706 | Sheffield et al. | Jul 2003 | A1 |
20030144829 | Geatz et al. | Jul 2003 | A1 |
20030181954 | Rezai | Sep 2003 | A1 |
20030181958 | Dobak | Sep 2003 | A1 |
20030208212 | Cigaina | Nov 2003 | A1 |
20030210147 | Humbard | Nov 2003 | A1 |
20030212440 | Boveja | Nov 2003 | A1 |
20030236558 | Whitehurst et al. | Dec 2003 | A1 |
20040006278 | Webb et al. | Jan 2004 | A1 |
20040088024 | Firlik et al. | May 2004 | A1 |
20040122484 | Hatlestad et al. | Jun 2004 | A1 |
20040122485 | Stahmann et al. | Jun 2004 | A1 |
20040133119 | Osorio et al. | Jul 2004 | A1 |
20040138516 | Osorio et al. | Jul 2004 | A1 |
20040138517 | Osorio et al. | Jul 2004 | A1 |
20040138647 | Osorio et al. | Jul 2004 | A1 |
20040138711 | Osorio et al. | Jul 2004 | A1 |
20040147969 | Mann et al. | Jul 2004 | A1 |
20040153129 | Pless et al. | Aug 2004 | A1 |
20040158119 | Osorio et al. | Aug 2004 | A1 |
20040158165 | Yonce et al. | Aug 2004 | A1 |
20040167580 | Mann et al. | Aug 2004 | A1 |
20040172085 | Knudson et al. | Sep 2004 | A1 |
20040172091 | Rezai | Sep 2004 | A1 |
20040172094 | Cohen et al. | Sep 2004 | A1 |
20040176812 | Knudson et al. | Sep 2004 | A1 |
20040176831 | Gliner et al. | Sep 2004 | A1 |
20040199212 | Fischell et al. | Oct 2004 | A1 |
20040249302 | Donoghue et al. | Dec 2004 | A1 |
20040249416 | Yun et al. | Dec 2004 | A1 |
20050004621 | Boveja et al. | Jan 2005 | A1 |
20050020887 | Goldberg | Jan 2005 | A1 |
20050021092 | Yun et al. | Jan 2005 | A1 |
20050021103 | DiLorenzo | Jan 2005 | A1 |
20050021104 | DiLorenzo | Jan 2005 | A1 |
20050021105 | Firlik et al. | Jan 2005 | A1 |
20050021106 | Firlik et al. | Jan 2005 | A1 |
20050021107 | Firlik et al. | Jan 2005 | A1 |
20050021118 | Genau et al. | Jan 2005 | A1 |
20050027284 | Lozano et al. | Feb 2005 | A1 |
20050033378 | Sheffield et al. | Feb 2005 | A1 |
20050033379 | Lozano et al. | Feb 2005 | A1 |
20050038484 | Knudson et al. | Feb 2005 | A1 |
20050049515 | Misczynski et al. | Mar 2005 | A1 |
20050049655 | Boveja et al. | Mar 2005 | A1 |
20050065562 | Rezai | Mar 2005 | A1 |
20050065573 | Rezai | Mar 2005 | A1 |
20050065574 | Rezai | Mar 2005 | A1 |
20050065575 | Dobak | Mar 2005 | A1 |
20050070971 | Fowler et al. | Mar 2005 | A1 |
20050075701 | Shafer | Apr 2005 | A1 |
20050075702 | Shafer | Apr 2005 | A1 |
20050101873 | Misczynski et al. | May 2005 | A1 |
20050119703 | DiLorenzo | Jun 2005 | A1 |
20050124901 | Misczynski et al. | Jun 2005 | A1 |
20050131467 | Boveja et al. | Jun 2005 | A1 |
20050131485 | Knudson et al. | Jun 2005 | A1 |
20050131486 | Boveja et al. | Jun 2005 | A1 |
20050131493 | Boveja et al. | Jun 2005 | A1 |
20050143786 | Boveja et al. | Jun 2005 | A1 |
20050148893 | Misczynski et al. | Jul 2005 | A1 |
20050148894 | Misczynski et al. | Jul 2005 | A1 |
20050148895 | Misczynski et al. | Jul 2005 | A1 |
20050153885 | Yun et al. | Jul 2005 | A1 |
20050154425 | Boveja et al. | Jul 2005 | A1 |
20050154426 | Boveja et al. | Jul 2005 | A1 |
20050165458 | Boveja et al. | Jul 2005 | A1 |
20050187590 | Boveja et al. | Aug 2005 | A1 |
20050192644 | Boveja et al. | Sep 2005 | A1 |
20050197590 | Osorio et al. | Sep 2005 | A1 |
20050245971 | Brockway et al. | Nov 2005 | A1 |
20050261542 | Riehl | Nov 2005 | A1 |
20050277998 | Tracey et al. | Dec 2005 | A1 |
20050283200 | Rezai et al. | Dec 2005 | A1 |
20050283201 | Machado et al. | Dec 2005 | A1 |
20050288600 | Zhang et al. | Dec 2005 | A1 |
20050288760 | Machado et al. | Dec 2005 | A1 |
20060009815 | Boveja | Jan 2006 | A1 |
20060074450 | Boveja | Apr 2006 | A1 |
20060079936 | Boveja | Apr 2006 | A1 |
20060094971 | Drew | May 2006 | A1 |
20060095081 | Zhou et al. | May 2006 | A1 |
20060106430 | Fowler et al. | May 2006 | A1 |
20060135877 | Giftakis et al. | Jun 2006 | A1 |
20060135881 | Giftakis et al. | Jun 2006 | A1 |
20060155495 | Osorio et al. | Jul 2006 | A1 |
20060167497 | Armstrong et al. | Jul 2006 | A1 |
20060173493 | Armstrong et al. | Aug 2006 | A1 |
20060173522 | Osorio | Aug 2006 | A1 |
20060190056 | Fowler et al. | Aug 2006 | A1 |
20060195163 | KenKnight et al. | Aug 2006 | A1 |
20060200206 | Firlik et al. | Sep 2006 | A1 |
20060212091 | Lozano et al. | Sep 2006 | A1 |
20060224067 | Giftakis et al. | Oct 2006 | A1 |
20060224191 | DiLorenzo | Oct 2006 | A1 |
20060241697 | Libbus et al. | Oct 2006 | A1 |
20060241725 | Libbus et al. | Oct 2006 | A1 |
20060293720 | DiLorenzo | Dec 2006 | A1 |
20070027486 | Armstrong | Feb 2007 | A1 |
20070027497 | Parnis | Feb 2007 | A1 |
20070027498 | Maschino et al. | Feb 2007 | A1 |
20070027500 | Maschino et al. | Feb 2007 | A1 |
20070032834 | Gliner et al. | Feb 2007 | A1 |
20070043392 | Gliner et al. | Feb 2007 | A1 |
20070055320 | Weinand | Mar 2007 | A1 |
20070073150 | Gopalsami et al. | Mar 2007 | A1 |
20070073355 | DiLorenzo | Mar 2007 | A1 |
20070088403 | Wyler et al. | Apr 2007 | A1 |
20070100278 | Frei et al. | May 2007 | A1 |
20070100392 | Maschino et al. | May 2007 | A1 |
20070142862 | DiLorenzo | Jun 2007 | A1 |
20070142873 | Esteller et al. | Jun 2007 | A1 |
20070150024 | Leyde et al. | Jun 2007 | A1 |
20070150025 | DiLorenzo et al. | Jun 2007 | A1 |
20070161919 | DiLorenzo | Jul 2007 | A1 |
20070162086 | DiLorenzo | Jul 2007 | A1 |
20070167991 | DiLorenzo | Jul 2007 | A1 |
20070173901 | Reeve | Jul 2007 | A1 |
20070173902 | Maschino et al. | Jul 2007 | A1 |
20070179534 | Firlik et al. | Aug 2007 | A1 |
20070179557 | Maschino et al. | Aug 2007 | A1 |
20070179558 | Gliner et al. | Aug 2007 | A1 |
20070208212 | DiLorenzo | Sep 2007 | A1 |
20070213785 | Osorio et al. | Sep 2007 | A1 |
20070233192 | Craig | Oct 2007 | A1 |
20070239210 | Libbus et al. | Oct 2007 | A1 |
20070244407 | Osorio | Oct 2007 | A1 |
20070249953 | Frei et al. | Oct 2007 | A1 |
20070249954 | Virag et al. | Oct 2007 | A1 |
20070255147 | Drew et al. | Nov 2007 | A1 |
20070255155 | Drew et al. | Nov 2007 | A1 |
20070260147 | Giftakis et al. | Nov 2007 | A1 |
20070260289 | Giftakis et al. | Nov 2007 | A1 |
20070265536 | Giftakis et al. | Nov 2007 | A1 |
20070272260 | Nikitin et al. | Nov 2007 | A1 |
20070282177 | Pilz | Dec 2007 | A1 |
20080033503 | Fowler et al. | Feb 2008 | A1 |
20080033508 | Frei et al. | Feb 2008 | A1 |
20080046035 | Fowler et al. | Feb 2008 | A1 |
20080064934 | Frei et al. | Mar 2008 | A1 |
20080071323 | Lowry et al. | Mar 2008 | A1 |
20080077028 | Schaldach et al. | Mar 2008 | A1 |
20080103548 | Fowler et al. | May 2008 | A1 |
20080114417 | Leyde | May 2008 | A1 |
20080119900 | DiLorenzo | May 2008 | A1 |
20080125820 | Stahmann et al. | May 2008 | A1 |
20080139870 | Gliner et al. | Jun 2008 | A1 |
20080146959 | Sheffield et al. | Jun 2008 | A1 |
20080161712 | Leyde | Jul 2008 | A1 |
20080161713 | Leyde et al. | Jul 2008 | A1 |
20080161879 | Firlik et al. | Jul 2008 | A1 |
20080161880 | Firlik et al. | Jul 2008 | A1 |
20080161881 | Firlik et al. | Jul 2008 | A1 |
20080161882 | Firlik et al. | Jul 2008 | A1 |
20080183096 | Snyder et al. | Jul 2008 | A1 |
20080183097 | Leyde et al. | Jul 2008 | A1 |
Number | Date | Country |
---|---|---|
1145736 | Oct 2001 | EP |
1486232 | Dec 2004 | EP |
2026870 | Feb 1980 | GB |
2079610 | Jan 1982 | GB |
2000064336 | Nov 2000 | WO |
2004036377 | Apr 2004 | WO |
2005007120 | Jan 2005 | WO |
2005053788 | Jun 2005 | WO |
2005067599 | Jul 2005 | WO |
2006050144 | May 2006 | WO |
2006122148 | Nov 2006 | WO |
2007066343 | Jun 2007 | WO |
2007072425 | Jun 2007 | WO |
2007124126 | Nov 2007 | WO |
2007124190 | Nov 2007 | WO |
2007124192 | Nov 2007 | WO |
2007142523 | Dec 2007 | WO |
2008045597 | Apr 2008 | WO |
Entry |
---|
Bachman, D.,S. et al.; “Effects of Vagal Volleys and Serotonin on Units of Cingulate Cortex in Monkeys;” Brain Research , vol. 130 (1977). pp. 253-269. |
Baevskii, R.M. “Analysis of Heart Rate Variability in Space Medicine;” Human Physiology, vol. 28, No. 2, (2002); pp. 202-213. |
Baevsky, R.M., et al.; “Autonomic Cardiovascular and Respiratory Control During Prolonged Spaceflights Aboard the International Space Station;”J. Applied Physiological, vol. 103, (2007) pp. 156-161. |
Boon, P., et al.; “Vagus Nerve Stimulation for Epilepsy, Clinical Efficacy of Programmed and Magnet Stimulation;” (2001); pp. 93-98. |
Boon, Paul, et al.; “Programmed and Magnet-Induced Vagus Nerve Stimulation for Refractory Epilepsy;”Journal of Clinical Neurophysiology vol. 18 No. 5; (2001); pp. 402-407. |
Borovikova, L.V., et al.; “Vagus Nerve Stimulation Attenuates the Systemic Inflammatory Response to Endotoxin;” Letters to Nature; vol. 405; (May 2000); pp. 458-462. |
Brack, Kieran E., et al.; “Interaction Between Direct Sympathetic and Vagus Nerve Stimulation on Heart Rate in the Isolated Rabbit Heart;”Experimental Physiology vol. 89, No. 1; pp. 128-139. |
Chakravarthy, N., et al.; “Controlling Synchronization in a Neuron-Level Population Model;” International Journal of Neural Systems, vol. 17, No. 2 (2007) pp. 123-138. |
Clark, K.B., et al.; “Posttraining Electrical Stimulation of Vagal Afferents with Concomitant Vagal Efferent Inactivation Enhances Memory Storage Processes in the Rat;” Neurobiology of Learning and Memory, vol. 70, 364-373 (1998) Art. No. NL983863. |
Digenarro, Giancarlo et al., “Ictal Heart Rate Increase Precedes EEG Discharge in Drug-Resistant Mesial Temporal Lobe Seizures,” Clinical Neurophysiology, No. 115, 2004, pp. 1169-1177. |
Frei, M.G., et al.; “Left Vagus Nerve Stimulation with the Neurocybernetic Prosthesis Has Complex Effects on Heart Rate and on Its Variability in Humans:” Epilepsia, vol. 42, No. 8 (2001); pp. 1007-1016. |
George, M.S., et al.; “Vagus Nerve Stimulation: A New Tool for Brain Research and Therapy;”Society of Biological Psychiatry vol. 47 (2000) pp. 287-295. |
“Heart Rate Variability—Standards of Measurement, Physiological Interpretation, and Clinical Use” Circulation—Electrophysiology vol. 93, No. 5; http://circ.ahajournals.orgicgi/content-nwifull/93/5/1043/F3. |
Henry, Thomas R.; “Therapeutic Mechanisms of Vague Name Stimulation;”. Neurology, vol. 59 (Supp 4) (Sep. 2002), pp. S3-S14. |
Hallowitz et al., “Effects of Vagal Volleys on Units of Intralaminar and Juxtalaminar Thalamic Nuclei in Monkeys;” Brain Research, vol. 130 (1977), pp. 271-286. |
Iasemidis; L.D., et al.; “Dynamical Resetting of the Human Brain at Epilepctic Seizures: Application of Nonlinear Dynamics and Global Optimization Techniques;” IEEE Transactions on Biomedical Engineering, vol. 51, No. 3 (Mar. 2004); pp. 493-50. |
Iasemidis; L.D., et al.; “Spatiotemporal Transition to Epileptic Seizures: A Nonlinear Dynamical Analysis of Scalp and Intracranial EEG Recordings;” Spatiotemporal Models in Biological and Artificial Systems; F.L. Silva et al. (Eds.) IOS Press, 1997; pp. 81-88. |
Iasemidis, L.D.; “Epileptic Seizure Prediction and Control” IEEE Transactions on Biomedical Engineering, vol. 50, No. 5 (May 2003); pp. 549-558. |
Kautzner, J., et al.; “Utility of Short-Term Heart Rate Variability for Prediction of Sudden Cardiac Death After Acute Myocardial Infarction” Acta Univ. Palacki. Olomuc., Fac. Med., vol. 141 (1998) pp. 69-73. |
Koenig, S.A., et al.; “Vagus Nerve Stimulation Improves Severely Impaired Heart Rate Variability in a Patient with Lennox-Gastaut-Syndrome” Seizure (2007) Article in Press—Yseiz-1305; pp. 1-4. |
Koo, B., “EEG Changes With Vagus Nerve Stimulation” Journal of Clinical Neurophysiology, vol. 18 No. 5 (Sep. 2001); pp. 434-441. |
Krittayaphong, M.D., et al.; “Heart Rate Variability in Patients with Coronary Artery Disease: Differences in Patients with Higher and Lower Depression Scores” Psychosomatic Medicine vol. 59 (1997) pp. 231-235. |
Leutmezer, F., et al.; “Electrocardiographic Changes at the Onset of Epileptic Seizures;” Epilepsia, vol. 44, No. 3; (2003); pp. 348-354. |
Lewis, M.E., et al.; “Vagus Nerve Stimulation Decreases Left Ventricular Contractility in Vivo in the Human and Pig Heart” The Journal of Physiology vol. 534, No. 2, (2001) pp. 547-552. |
Li, M., et al.; “Vagal Nerve Stimulation Markedly Improves Long-Term Survival After Chronic Heart Failure in Rats;” Circulation (Jan. 2004) pp. 120-124. |
Licht, C.M.M.; Association Between Major Depressive Disorder and Heart Rate Variability in the Netherlands Study of Depression and Anxiety (Nesda); Arch. Gen Psychiatry, vol. 65, No. 12 (Dec. 2008); pp. 1358-1367. |
Lockard et al., “Feasibility and Safety of Vagal Stimulation in Monkey Model;” Epilepsia, vol. 31 (Supp. 2) (1990), pp. S20-S26. |
Long, Teresa J. et al., “Effectiveness of Heart Rate Seizure Detection Compared to EEG in an Epilepsy MoitoringUnit (EMU),” abstract of AES Proceedings, Epilepsia, vol. 40, Suppl. 7, 1999, p. 174. |
McClintock, P., “Can Noise Actually Boost Brain Power” Physics World Jul. 2002; pp. 20-21. |
Mori, T., et al.; “Noise-Induced Entrainment and Stochastic Resonance in Human Brain Waves” Physical Review Letters vol. 88, No. 21 (2002); pp. 218101-1-218101-4. |
Mormann, F., “Seizure prediction: the long and winding road,” Brain 130 (2007), 314-333. |
Nouri, M.D.; “Epilepsy and the Autonomic Nervous System” emedicine (updated May 5, 2006); pp. 1-14; http://www.emedicine.com/neuro/topic658.htm. |
O'Donovan, Cormac A. et al., “Computerized Seizure Detection Based on Heart Rate Changes,” abstract of AES Proceedings, Epilepsia, vol. 36, Suppl. 4, 1995, p. 7. |
O'Regan, M.E., et al.; “Abnormalities in Cardiac and Respiratory Function Observed During Seizures in Childhood” Developmental Medicine & Child Neurlogy, vol. 47 (2005) pp. 4-9. |
Osorio, Ivan et al., “An Introduction to Contingent (Closed-Loop) Brain Electrical Stimulation for Seizure Blockage, to Ultra-Short-Term Clinical Trials, and to Multidimensional Statistical Analysis of Therapeutic Efficacy,” Journal of Clinical Neurophysiology, vol. 18, No. 6, pp. 533-544, 2001. |
Osorio, Ivan et al., “Automated Seizure Abaatement in Humans Using Electrical Stimulation,” Annals of Neurology, vol. 57, No. 2, pp. 258-268, 2005. |
Pathwardhan, R.V., et al., Control of Refractory status epilepticus precipitated by anticonvulasnt withdrawal using left vagal nerve stimulation: a case report, Surgical Neurology 64 (2005) 170-73. |
Poddubnaya, E.P., “Complex Estimation of Adaptation Abilities of the Organism in Children Using the Indices of Responsiveness of the Cardiovascular System and Characteristics of EEG” Neurophysiology vol. 38, No. 1 (2006); pp. 63-74. |
Robinson, Stephen E et al., “Heart Rate Variability Changes As Predictor of Response to Vagal Nerve Stimulation Therapy for Epilepsy,” abstract of AES Proceedings,Epilepsia, vol. 40, Suppl. 7, 1999, p. 147. |
Rugg-Gunn, F.J., et al.; “Cardiac Arrhythmias in Focal Epilepsy: a Prospective Long-Term Study” www.thelancet.com vol. 364 (2004) pp. 2212-2219. |
Sajadieh, A., et al.; “Increased Heart Rate and Reduced Heart-Rte Variability are Associated with Subclinical Inflammation in Middle-Aged and Elderly Subjects with No Apparent Heart Disease” European Heart Journal vol. 25, (2004); pp. 363-370. |
Schernthaner, C., et al.; “Autonomic Epilepsy—The Influence of Epileptic Discharges on Heart Rate and Rhythm” The Middle European Joural of Medicine vol. 111, No. 10 (1999) pp. 392-401. |
Sunderam, Sridhar et al., “Vagal and Sciatic Nerve Stimulation Have Complex, Time-Dependent Effects on Chemically-Induced Seizures: A Controlled Study,” Brain Research, vol. 918, pp. 60-66, 2001. |
Terry et al.; “The Implantable Neurocybernetic Prosthesis System”, Pacing and Clinical Electrophysiology, vol. 14, No. 1 (Jan. 1991), pp. 86-93. |
Tubbs, R.S., et al.; “Left-Sided Vagus Nerve Stimulation Decreases Intracranial Pressure Without Resultant Bradycardia in the Pig: A Potential Therapeutic Modality for Humans” Child's Nervous System Original Paper; Springer-Verlag 2004. |
Umetani, M.D., et al.; “Twenty-Four Hour Time Domain Heart Rate Variability and Heart Rate: Relations to Age and Gender Over Nince Decades” JACC vol. 31, No. 3; (Mar. 1998); pp. 593-601. |
Van Elmpt, W.J.C., et al.; “A Model of Heart Rate Changes to Detect Seizures in Severe Epilepsy” Seizure vol. 15, (2006) pp. 366-375. |
Vonck, K., et al. “The Mechanism of Action of Vagus Nerve Stimulation for Refractory Epilepsy—The Current Status”, Journal of Neurophysiology, vol. 18 No. 5 (2001), pp. 394-401. |
Weil, Sabine et al, “Heart Rate Increase in Otherwise Sublinical Seizures Is Different in Temporal Versus Extratemporal Seizure Onset: Support for Temporal Lobe Automatic Influence,” Epileptic Disord., vol. 7, No. 3, Sep. 2005, pp. 199-204. |
Woodbury, et al., “Vagal Stimulation Reduces the Severity of Maximal Electroshock Seizures in Intact Rats. Use of a Cuff Electrode for Stimulating and Recording”; Pacing and Clinical Electrophysiology, vol. 14 (Jan. 1991), pp. 94-107. |
Zabara, J.; “Neuroinhibition of Xylaine Induced Emesis” Pharmacology & Toxicology, vol. 63 (1988) pp. 70-74. |
Zabara, J. “Inhibition of Experimental Seizures in Canines by Repetivie Vagal Stimulation” Epilepsia vol. 33, No. 6 (1992); pp. 1005-1012. |
Zabara, J., et al.; “Neural Control of Circulation I”The Physiologist, vol. 28 No. 4 (1985); 1 page. |
Zabara, J., et al.; “Neuroinhibition in the Regulation of Emesis” Space Life Sciences, vol. 3 (1972) pp. 282-292. |
Zijlmans, Maeike et al., “Heart Rate Changes and ECG Abnormalities During Epileptic Seizures: Prevalence and Definition of an Objective Clinical Sign,” Epilepsia, vol. 43, No. 8, 2002, pp. 847-854. |
Number | Date | Country | |
---|---|---|---|
60525501 | Nov 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10997540 | Nov 2004 | US |
Child | 12315390 | US |